Related Experiment Videos
The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells
C Pellat-Deceunynck1, M P Mellerin, N Labarrière
1Inserm U463, Institut de Biologie, Nantes, France. cpellat@nantes.inserm.fr
Abstract:
In this study, we have investigated the mRNA expression of the cancer germ-line genes MAGE, BAGE, GAGE, RAGE and the tumor-overexpressed gene PRAME by human myeloma cell lines and malignant plasma cells from patients with multiple myeloma (MM). By reverse transcription-PCR, we show that all myeloma cell lines (n = 16) express at least one of these genes, except RAGE-1 that was never expressed. We show that malignant plasma cells from the majority of MM patients (n = 21) expressed MAGE-1, MAGE-3 and PRAME. On the contrary, polyclonal reactive plasma cells did not express any of these genes. By flow cytometry, we show that mage-1 protein is expressed within myeloma cells and cell lines and that anti-mage-1.HLA-A1 cytotoxic T lymphocytes efficiently killed MAGE-1+HLA-A1+ MDN myeloma cells. Taken together, our data show that mage-1 and mage-3 could constitute specific targets for tumor immunotherapy of MM patients.
Insights
Cancer germ-line genes like MAGE-1 and MAGE-3 are expressed in multiple myeloma (MM) cells. These genes offer potential targets for developing novel immunotherapies against MM.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Cancer germ-line genes (e.g., MAGE, BAGE, GAGE, RAGE) and tumor-overexpressed genes (e.g., PRAME) are implicated in various cancers.
- Multiple myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells.
Purpose of the Study:
- To investigate the expression of cancer germ-line genes (MAGE, BAGE, GAGE, RAGE) and PRAME in human myeloma cell lines and malignant plasma cells from MM patients.
- To evaluate the potential of these genes as targets for multiple myeloma immunotherapy.
Main Methods:
- Reverse transcription-polymerase chain reaction (RT-PCR) was used to analyze mRNA expression.
- Flow cytometry was employed to detect protein expression.
- Cytotoxicity assays were performed using anti-MAGE-1.HLA-A1 cytotoxic T lymphocytes.
Main Results:
- All tested myeloma cell lines (n=16) expressed at least one of the investigated genes, excluding RAGE-1.
- MAGE-1, MAGE-3, and PRAME were expressed in malignant plasma cells from the majority of MM patients (n=21).
- MAGE-1 protein was detected in myeloma cells, and MAGE-1+HLA-A1+ cells were effectively killed by specific cytotoxic T lymphocytes.
Conclusions:
- MAGE-1 and MAGE-3 are specifically expressed in multiple myeloma cells and represent promising targets for immunotherapy.
- The findings support the development of targeted immunotherapies for MM patients based on MAGE-1 and MAGE-3 expression.